Objective: Fosaprepitant, an intravenous neurokinin-1 (NK1) receptor antagonist used to prevent chemotherapy-induced nausea and vomiting, is known to cause local adverse events at peripheral infusion sites, including vascular pain and phlebitis. Although female sex and the number of chemotherapy cycles have been reported as risk factors, the association between concomitant antineoplastic agents and local adverse events has not been comprehensively investigated.
Methods: This retrospective study included patients who received peripheral intravenous fosaprepitant between July 2021 and July 2022. Peripheral intravenous infusion–related local adverse events (PILAEs) were defined as vascular pain, erythema, induration, phlebitis, and extravasation documented in the medical records. Patient characteristics and concomitant antineoplastic agents were compared according to the occurrence of PILAEs. Multivariate logistic regression analysis was performed to identify independent factors associated with PILAEs.
Results: Of the 260 patients included, 89 (34.2%) developed PILAEs. Multivariate analysis identified the number of chemotherapy cycles, female sex, and concomitant etoposide administration as independent factors associated with the development of PILAEs.
Conclusions: Concomitant use of etoposide may increase the risk of PILAEs in patients receiving fosaprepitant. When selecting antiemetic therapy and planning infusion strategies, the type of concomitant antineoplastic agent should be considered.
Constipation is common among hospitalized patients with cancer and may adversely affect their quality of life as well as the continuation of their anticancer treatment. The Constipation Risk Assessment Scale (CRAS), developed in the United States, has been reported to demonstrate favorable content validity, predictive validity, and interrater reliability in China. To our knowledge, there have been no reports of CRAS use in Japan; therefore, beginning in January 2022, pharmacists at our hospital initiated the use of the Japanese version, CRAS-J, on admission for hospitalized patients with cancer. Constipation was defined as the occurrence of “no bowel movement for 2 consecutive days” within 7 days of hospital admission. To evaluate the usefulness and predictive validity of CRAS-J, bowel management outcomes were compared before and after its introduction. This retrospective study reviewed the medical records of eligible cancer inpatients admitted during the pre-introduction period (January 2020 – December 2021) and the post-introduction period (January 2022 – June 2024). No significant differences in patient background characteristics were observed between the two periods. The incidence of constipation decreased significantly after the introduction of CRAS-J [60/85 cases (70.6%) before introduction vs 44/83 cases (53.0%) after introduction; P = 0.026]. Furthermore, the mean CRAS-J score was significantly higher in the “constipation present” group (n = 44; 15.25) than in the “constipation absent” group (n = 39; 12.97) (P = 0.012). These findings support the usefulness of CRAS-J for improving bowel management in hospitalized patients with cancer and suggest that the CRAS-J score may serve as one indicator of early constipation after admission.
The medication notebook is a valuable tool for preventing drug–drug interactions and duplicate prescriptions, facilitating the sharing of medication information with healthcare providers, and confirming medication histories during disasters. It is therefore important for foreign residents receiving medical care in Japan. This study aimed to clarify the level of awareness and understanding of the medication notebook among foreign residents.
Between July 2023 and June 2025, a questionnaire survey was conducted among foreign residents who visited a single community pharmacy in Tsu City, Mie Prefecture, Japan, to receive prescription medications. The survey collected information on patient characteristics and their understanding of the roles of the medication notebook. From July 2024 onward, additional questions were included to explore reasons for bringing or not bringing the notebook.
Responses were obtained from 39 participants (response rate: 97.5%), of whom 13 brought their medication notebooks at the time of the visit. Understanding of the notebook’s roles was significantly higher among users than non-users, including its functions in preventing drug interactions and duplicate prescriptions, enabling information sharing with healthcare providers, and providing medication histories during disasters. The most frequently cited reasons for bringing the notebook were self-confirmation of medications and recommendations from pharmacies, whereas the main reasons for not bringing the notebook were a perceived lack of necessity, inconvenience, and insufficient awareness of its purpose.
These findings indicate that limited awareness of the medication notebook and insufficient understanding of its roles and practical benefits contribute to its low utilization among foreign residents in Japan.
LGBT individuals often face barriers to healthcare and health disparities due to discrimination and prejudice in medical settings. Hospital pharmacists frequently encounter patients’ gender identity and partner relationships through medication counseling and interviews, positioning them as key professionals in LGBT-inclusive care. However, in Japan, no studies have systematically evaluated hospital pharmacists’ attitudes or clinical competency regarding LGBT patients, and the actual situation remains unclear. This exploratory cross-sectional study aimed to clarify the current status of Attitudinal Awareness, Basic Knowledge, Clinical Preparedness, and Clinical Training regarding LGBT patients among hospital pharmacists using the Japanese version of the LGBT Development of Clinical Skills Scale (LGBT-DOCSS). An anonymous web-based survey was conducted among 464 pharmacists affiliated with the Oita Prefecture Hospital Pharmacists Association. Valid responses were obtained from 112 participants (response rate: 24.1%). The mean total LGBT-DOCSS score was 3.89 ± 0.69. Attitudinal Awareness scores were relatively high (6.01 ± 1.03), whereas Clinical Preparedness (2.29 ± 1.05) and Clinical Training (1.32 ± 0.83) scores were markedly low. In addition, 98 respondents (87.5%) reported that they had received no LGBT-related lectures or training. Although the respondents in this study had positive attitudes toward LGBT individuals, the findings suggest that they may not have been sufficiently prepared for practical clinical interactions with LGBT patients. Further consideration is needed regarding how practical LGBT healthcare education should be incorporated into undergraduate pharmacy education and postgraduate training.
Belzutifan is a novel oral anticancer agent that inhibits hypoxia-inducible factor-2α (HIF-2α) and is associated with characteristic adverse events, including anemia and hypoxia. This study evaluated the incidence and clinical course of adverse events in patients who received belzutifan therapy in an outpatient setting, with a particular focus on hypoxia.
This single-center retrospective observational study included seven patients with renal cell carcinoma who received belzutifan treatment at our institution between August 2025 and February 2026. Patient education and regular outpatient monitoring were performed as part of routine clinical care. Patient characteristics, the incidence and severity of adverse events, hypoxia outcomes, and treatment discontinuation were evaluated.
Anemia occurred in all patients, with grade 3 anemia observed in two patients. Hypoxia occurred in four patients, all of whom required hospitalization and oxygen therapy, and three subsequently discontinued treatment. The median time to the onset of hypoxia was 26 days, and some cases developed before scheduled outpatient visits.
Severe hypoxia occurred in some patients despite patient education and regular outpatient follow-ups. Although limited by the small sample size, these findings suggest that hypoxia may not always be detected under the current outpatient management system before it progresses to a severe condition. In addition to careful monitoring, further investigation of risk stratification approaches that incorporate patient characteristics and pharmacokinetic factors is warranted.
We evaluated a secure medical generative artificial intelligence (AI) environment to verify active ingredient dose equivalence between patients’ own medications and hospital formulary alternatives during the reconciliation of patients’ own medications. Data for patients admitted between January 1 and March 31, 2026, and initially entered into a Microsoft Access-based checking system were analyzed using manual pharmacist calculations as the reference standard. For single-ingredient pairs, the Access system and an AI-alone condition were assessed; for fixed-dose combination pairs, only the AI-alone condition was assessed. Calculated values and final judgments were compared. As an exploratory analysis, an AI condition supplied with investigator-verified composition information from electronic package inserts was applied to discrepant single-ingredient pairs and all fixed-dose combination pairs. Among 6,866 single-ingredient pairs, the Access system achieved sensitivity and specificity of 100.00% and 99.88%, respectively, while the AI-alone condition yielded a sensitivity of 98.44% and a specificity of 99.99%. For 151 fixed-dose combination pairs, specificity was low (54.00%) because many equivalent pairs were misclassified as non-equivalent; sensitivity was not calculated because the reference standard identified only one non-equivalent pair. AI-alone discrepancies were mainly attributable to errors in extracting composition information, and repeated analyses of the 18 discrepant single-ingredient pairs reproduced the same discrepancies. When investigator-verified composition information was provided, calculated values and final judgments were concordant with manual calculations for all 18 discrepant single-ingredient pairs and all 151 fixed-dose combination pairs. These findings suggest that externally provided composition information and pharmacist review are important when using medical generative AI for this task.
The early treatment of postprandial hyperglycemia (PPHG) is important for preventing arteriosclerosis. Therefore, community pharmacies are expected to play an active role in its management. In this study, we first developed a simple screening method for PPHG that can be implemented in community pharmacies and then evaluated its usefulness in local residents.
To develop the screening method, five healthy adults in their twenties ingested 10.8 g of glucose, and their blood glucose (BG) levels were measured over time. Based on the observation that BG levels peaked 30 minutes after ingestion, a BG level ≥ 140 mg/dL at 30 minutes (BG-post) was defined as PPHG, and participants were classified into a high BG-post (Hi-BG-post) group.
Using this screening method, data were subsequently collected from local residents at a community health support event. Forty-nine participants with no history of diabetes or hyperglycemia and who were not receiving any medication were selected for the analysis.
The prevalence of Hi-BG-post was 49%. BG-post levels were significantly correlated with levels of low-density lipoprotein cholesterol (LDL-C), but not with pre-treatment BG levels (BG-pre) or HbA1c. Among individuals with Hi-BG-post, those with LDL-C ≥ 120 mg/dL had significantly higher blood pressure than those with lower LDL-C levels. The cut-off value of BG leading to this correlation was determined to be 44 mg/dL through multiple regression analysis.
These findings suggest that this simple screening method is a useful tool for identifying PPHG and indicate the possibility of early management by community pharmacies for local residents at risk of PPHG.
Immune-related adverse events (irAE) are adverse drug reactions that are characteristic of immune checkpoint inhibitors (ICI). IrAE can occur in multiple organs and have a wide range of onset times, making early detection difficult. Therefore, a new protocol using protocol-based pharmacotherapy management (PBPM) aimed at the early detection of irAE was developed and implemented by pharmacists at Mie Chuo Medical Center in Tsu, Japan. The protocol provides steps and instructions for blood and urine tests for outpatients receiving an ICI regimen when irAE-related tests have not been performed within the past 3 months. The clinical tests included in the protocol are free triiodothyronine, free thyroxine, thyroid-stimulating hormone, adrenocorticotropic hormone, serum cortisol, Krebs von den Lungen-6, hemoglobin A1c, blood glucose levels, and urinalysis. This study evaluated the usefulness of the protocol and examined its impact on physician behavior, using data for 277 regimens pre-PBPM and 284 regimens post-PBPM. The percentage of regimens in which all test items were performed increased from 8.3% to 90.5% (P < 0.001). Furthermore, the percentage of regimens in which all test items were ordered only by physicians increased from 8.3% to 15.8% (P = 0.006). This protocol may be useful for the continuous monitoring of irAE in patients receiving ICI regimens. Moreover, the protocol may contribute to changes in physicians’ behavior by raising their awareness of the importance of irAE-related blood and urine tests.
The Ministry of Health, Labour and Welfare began offering electronic prescription services on January 26, 2023. This electronic prescription service links master data for standardized YJ codes (drugs), generic name prescription codes, and electronic receipt codes, enabling the sharing of prescription and dispensing information between medical institutions and pharmacies. However, the introduction of electronic prescriptions presents several challenges, including the registration of Healthcare Public Key Infrastructure electronic certificates, verification of prescription linkage with billing systems, development of electronic medical record master data, and the design of workflows involving nearby pharmacies. In this paper, we report cases in which investigation and countermeasures were required to address these issues. Prior to implementation, only 14.8% of physicians were able to issue electronic prescriptions; however, a survey conducted by the medical affairs division showed that this proportion increased to 52.7% after 7 months. Verification of prescription sharing with nearby pharmacies revealed that prescription information was not being shared for some functions, and inconsistencies arose due to differences in billing systems across companies. In addition, during the development of electronic medical record master data, numerous inconsistencies were identified between the standard master data for electronic prescriptions and that for topical medications at our hospital.